How might FDA regulation of LDTs change in the future?

The FDA has been working to expand its oversight of Laboratory Developed Tests for many years. In 2024, the FDA published a final rule proposing to phase in FDA oversight of LDTs over a four-year period — this would eventually require LDTs to submit performance data to the FDA and potentially undergo formal review. However, the implementation timeline and scope of this rule may be affected by legal challenges from the laboratory industry and changes in regulatory priorities under different administrations. OncuraKit and Yenos Analytical are monitoring these regulatory developments closely and are committed to maintaining compliance with all applicable regulations. We believe our four published peer-reviewed studies provide a strong foundation for any future FDA submission requirements.